Can Austedo Titration Cause Depression?
Yes, Austedo (deutetrabenazine) carries a significant risk of depression and suicidal ideation, particularly during titration, and this risk is serious enough to warrant a boxed warning from the FDA. The drug is contraindicated in patients with untreated or inadequately controlled depression, and in those with suicidal ideation 1.
FDA Boxed Warning and Contraindications
The FDA label explicitly states that Austedo can cause depression, worsening of existing depression, and suicidal thoughts or actions in people with Huntington's disease 1. The drug should not be initiated in patients who:
- Have untreated depression or depression not well-controlled by medication
- Are actively suicidal or have suicidal ideation
- Are taking MAOIs (within 14 days) 1
Clinical Evidence During Titration
Depression during titration appears to be dose-dependent and occurs early in treatment. In the ARM-TD study, depression rates were low overall (1.7% in both deutetrabenazine and placebo groups), with depressed mood occurring in 1.7% versus 1.7% respectively 2. However, real-world pharmacovigilance data from the FAERS database identified depression as one of the most remarkable safety signals, along with suicidal ideation 3.
The majority of adverse events, including psychiatric symptoms, were reported within the initial month of treatment, with a median time to onset of 40.5 days 3. This temporal pattern suggests heightened vigilance is needed during the titration phase.
Titration-Specific Considerations
During dose escalation:
- Start low and titrate slowly: The standard titration involves weekly increases over 8 weeks to reach optimal dosing 4
- Monitor closely during weeks 1-4: This is when psychiatric adverse events are most likely to emerge 3
- Assess mood at each dose adjustment: The FDA label recommends regular assessment of patient status beginning within 1-2 weeks of therapy initiation 1
Risk Stratification
Patients with pre-existing psychiatric conditions require enhanced monitoring. Before initiating Austedo, clinicians must assess for:
- History of depression, anxiety, or psychosis
- Previous suicidal thoughts or attempts
- Current emotional or mental problems 1
The drug label specifically warns about the emergence or worsening of depression, requiring appropriate discussion and patient counseling before therapy initiation 5.
Management Algorithm
If depression emerges during titration:
- Immediately reduce the dose or discontinue if severe depression or suicidal ideation develops 1
- Hold at current dose if mild depressive symptoms emerge and reassess within 3-7 days
- Consider slower titration intervals (every 2 weeks instead of weekly) in high-risk patients
- Initiate or optimize antidepressant therapy concurrently if depression develops, though note that SSRIs can be used safely with Austedo 6
Comparative Safety Profile
Importantly, the psychiatric adverse event rates with deutetrabenazine appear lower than with some antidepressants themselves. Studies show lower manic switch rates compared to pharmaceutical antidepressants 7, and anxiety rates were actually lower in the deutetrabenazine group (3.4%) versus placebo (6.8%) in the ARM-TD study 2.
Long-Term Safety Data
In the open-label extension study (ARC-HD), with exposure up to 145 weeks, depression occurred in 32% of rollover patients and 22% of switch patients, while suicidality occurred in 9% and 5% respectively 8. These rates remained stable over time, suggesting the risk doesn't necessarily increase with continued treatment beyond the titration phase.
Critical Monitoring Points
Patients and caregivers must be instructed to immediately report:
- New or worsening depression
- Unusual changes in mood or behavior
- Suicidal thoughts or self-harm ideation
- Increased anxiety or agitation 1
If urgent psychiatric symptoms develop, patients should seek immediate medical attention at the nearest emergency facility 9.
The evidence clearly demonstrates that while depression can occur during Austedo titration, careful patient selection, slow dose escalation, and vigilant monitoring can mitigate this risk. The absolute contraindication in untreated depression must be respected, and any emergence of significant depressive symptoms warrants immediate dose adjustment or discontinuation.